Zach System (Zambon) SpA are now an active out-license user, check out their available dossiers now!
Latvian company PharmIdea are now active on Genericlicensing.com with Atosiban available! Click here to connect direct.
Greek company GAP SA are our newest out-licensing company - check out their available products here now!
Abdi Ibrahim have upgraded to Featured status and updated their product list. Click here to see more!
Pharma Dreams have a UK MA available on Diclofenac Sodium, SR Tablet - 75, 100mg - click here to contact direct!
An assessment of innovation in the generic pharmaceutical industry.
· The registration of the drug is expected to take place by January 2013 · Dutasteride follows the submission of Dexketoprofen and Cilostazol over the past year
in Fight Against Breast Cancer with First Health Initiative powered by Spotify
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement - Revised Agreement Simplifies Alliance by Streamlining Operational Responsibilities Consistent with Each Company's Strategic Priorities -.
(Reuters) - Swiss drugmaker Roche Holding AG believes the threat from so-called biosimilar copies of its cancer drugs has been pushed back as companies developing the cut-price biotech medicines face development hurdles. David Loew, the firm's marketing head, said on Wednesday that he did not now expect any biosimilar versions of Roche's blockbuster antibody drug Rituxan, one of the first to face such competition, before the first quarter of 2015.
Mylan announced that it and its subsidiary, Mylan Pharmaceuticals, have entered into a settlement agreement with Pfizer, Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Atlas Venture leads Series A financing with Partners Innovation Fund and The Medicines Company; IND filing targeted for 1H13 CAMBRIDGE, Mass. - September 10th, 2012 - Annovation Biopharma, a biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8M in a Series A financing led by Atlas Venture, Partners Innovation Fund (PIF), and new strategic investor The Medicines Company (NASDAQ: MDCO). The funding, which may be expanded up to $11M, is expected to enable pre-clinical development through clinical proof of concept of Annovation's lead, next generation novel anesthetic, based on technology from Dr. Douglas Raines's Laboratory in the Department of Anesthesia, Critical Care, and Pain Medicine at Massachusetts General Hospital (MGH).
Panacea Pharma Projects - New listed company now live, offering Pharmacovigilance services! Check out their free document downloads
EBD Group and Generic Pharma 2.0 announce Pharma Meetings, a new conference productivity platform, to be launched at CPhI Madrid on October 9, 2012
Check out the 2 new presentations uploaded by 1 of our Featured out-license clients, Synchrony Pharma Ltd
New Pharma Focuses on Think60 Movement BARRIE, ON, June 5th, 2012 – New Pharma is evolving into a community for strategic thinkers and decision makers within the pharmaceutical industry Responding to the need for fast, high-quality information focused on disruption and innovation in the industry, New Pharma Magazine is evolving into a community where thought leaders and decision makers can be introduced to and share information and ideas. The content on the new website will be presented in a variety of formats including webinars, videos and articles. Prominent thought leaders throughout the world will also be featured in the New Pharma community, providing opinions via comments and Twitter chats. The community will open its gates June 13th, and can be found at www.NewPharmaThinkers.com. New Pharma's power comes from its ability to regularly stimulate members of its community to think about the future. Articles and media are delivered each week through its 'weekly stimulants,' a message to subscribers listing key issues and providing a quick and easy way for them to read, comment, like and share those topics that interest them the most. Nearly half of the participants in a recent poll said that they spend more than three hours each week thinking about the future of their business and/or industry. "It has become our mission to bring those big thinkers together into one community and also to provide them with innovative, disruptive industry content to fuel discussions and create some added value" says Asa Cox, Editor in Chief. New Pharma's evolution to a community of thinkers is based on the Think60 movement – an idea that business leaders should be spending upwards of 60 minutes in a given day - roughly 10% of a typical work week - thinking about the future of their business. New Pharma Thinkers will be available on June 13th, 2012. To become a member of this community, please visit www.NewPharmaThinkers.com. New Pharma Thinkers is owned by Generic Pharma 2.0. GP2.0 helps companies achieve transformational growth through smart ideas and innovative opportunities. It has the largest global network in the industry; offering web-platforms and the highest-level expertise for strategic advice, investments, business development and digital engagement. Media Contact: Asa Cox, Editor in Chief T: (705) 615-1500, F: (705) 615-1501 Asa.Cox@genericpharma20.com www.NewPharmaThinkers.com Read more: New Pharma Focuses on Think60 Movement - FiercePharma http://www.fiercepharma.com/press-releases/new-pharma-focuses-think60-movement#ixzz1y5joyzdH Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma
Join now, for FREE, to get your digital magazine flip book!
The maker of the widely used Avastin cancer drug said Tuesday that it is warning doctors, hospitals and patient groups that a counterfeit version of the medicine has been found in the U.S.
Watson Pharmaceuticals has filed for approval in the US to market a generic version of Bayer's oral contraceptive product Beyaz, prompting an immediate lawsuit from Bayer and partner Merck & Cie.
GlaxoSmithKline delivers, but general pipeline fears still hold the share price down.
Generic Licensing will soon be offering new, great looking, company profiles including new features such as adding events, documents & news! Stay Tuned!
With the tremendous growth in sales in emerging markets expected over the next 10 years, now is the time to join the BRANDED GENERICS conference to find out whether this opportunity for sales expansion is right for you. You will meet face-to-face with
Uncover the next level and latest global developments in generics and evaluate upcoming opportunities. Assess and capitalize on pharmerging market growth to maximize your ROI. ‘NEW’! Legal Debate featuring in-house counsel from innovator and generic companies. Leverage key success factors in profitable and sustainable partnerships. Differentiating generics through different drug delivery systems or greater brand recognition. Reinforce your positioning and grow your market share through branded generics. Understand and evaluate strategies in the next phase of generic medicines from ‘Commodity’ to ‘Super-generics’.
We are proud to present our 4th Annual Drug Discovery Partnership: Filling the Pipeline Conference! Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs. With key products suffering patent expiration in coming years, the need for new approaches to accelerate development of new chemical entities to treat severely unmet medical needs is more urgent than ever. Much of this work can only be done through the collaborative work of public and private industry. More than ever, drug discovery professionals from across the industry need to come together to share their technology, insight and experiences to help fill the quickly drying pipeline of new and effective drugs!
Established in the year 1981, GCCPL is an ambitious Indian pharmaceutical, Functional Food & Nutraceuticals company; partners with its principals & clients alike to deliver customized solutions that resolve their significant issues and create lasting competitive advantage. Utilizing decades of industry experience and functional expertise, GCCPL looks beyond standard solutions to develop new insights, mobilize resources, drive tangible results, and make our partner more capable of meeting challenges in the burgeoning Indian pharmaceutical market.
Lupin Ltd. (LPC), the world’s largest maker of drugs to fight tuberculosis, is considering selling its unit that markets medicines in India, said two people with knowledge of the matter. Founding shareholders who own a combined 47 percent of the Mumbai-based company have started the process of finding a buyer for the operations, said the people, who declined to be identified because the discussions are private. The Indian business may be worth at least $1 billion, one person said.